MA39778A - Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants - Google Patents

Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants

Info

Publication number
MA39778A
MA39778A MA039778A MA39778A MA39778A MA 39778 A MA39778 A MA 39778A MA 039778 A MA039778 A MA 039778A MA 39778 A MA39778 A MA 39778A MA 39778 A MA39778 A MA 39778A
Authority
MA
Morocco
Prior art keywords
gated sodium
sodium channel
channel modulators
sulfonamide compounds
voltage gated
Prior art date
Application number
MA039778A
Other languages
English (en)
Inventor
Moloy Banerjee
Amit Kumar Das
Rajender Kumar Kamboj
Talha Hussain Khan
Rajeshkumar Maganlal Loriya
Venkata P Palle
Vidya Ramdas
Deepak Sahebrao Walke
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA39778A publication Critical patent/MA39778A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne le composé de formule (i) dans laquelle les substituants sont tels que décrits dans la description, et leur utilisation dans un médicament destiné au traitement de maladies, de troubles associés à l'inhibition des canaux sodiques potentiel-dépendants (vgsc) en particulier na
MA039778A 2014-03-29 2015-03-27 Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants MA39778A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1170MU2014 2014-03-29
IN566MU2015 2015-02-20

Publications (1)

Publication Number Publication Date
MA39778A true MA39778A (fr) 2017-02-08

Family

ID=54239471

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039778A MA39778A (fr) 2014-03-29 2015-03-27 Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants

Country Status (7)

Country Link
US (1) US20170137415A1 (fr)
EP (1) EP3126360A1 (fr)
AU (1) AU2015242219A1 (fr)
CA (1) CA2944115A1 (fr)
MA (1) MA39778A (fr)
TW (1) TW201623264A (fr)
WO (1) WO2015151001A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
CN108699015A (zh) 2015-12-18 2018-10-23 默沙东公司 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物
ES2897998T3 (es) * 2016-10-27 2022-03-03 Bristol Myers Squibb Co Inhibidores de la acilsulfonamida del NaV1.7
WO2018163077A1 (fr) 2017-03-08 2018-09-13 Lupin Limited Composés indanyle utilisés en tant que modulateurs de canaux sodiques dépendant de la tension
EP3601273B1 (fr) 2017-03-24 2021-12-01 Genentech, Inc. Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques
CN110621669A (zh) 2017-05-04 2019-12-27 巴斯夫欧洲公司 防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
AR116020A1 (es) 2018-09-03 2021-03-25 Bayer Ag COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
WO2020048828A1 (fr) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020509A2 (fr) 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Medicament pour lutter contre des maladies virales
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
WO2007109324A2 (fr) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Bloqueurs puissants et sélectifs du canal sodique nav1.7
WO2008046049A1 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés de spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one et composés connexes utilisables pour traiter des maladies dont la médiation est assurée par les canaux sodiques, comme la douleur
EP2073806B1 (fr) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Utilisation de composés de spiro-oxindole comme agents thérapeutiques
WO2008046084A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
WO2008046087A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
WO2010035166A1 (fr) 2008-09-23 2010-04-01 Pfizer Limited Dérivés de benzamide
WO2010045197A1 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010053998A1 (fr) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Dérivés d'indole spiro-condensés utilisables en tant qu'inhibiteurs des canaux sodiques
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010151597A1 (fr) 2009-06-26 2010-12-29 Schering Corporation Procédés d'utilisation de pyrrolo-benzo-1,4-diazines en tant que bloqueurs de canaux sodiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2771472A1 (fr) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Derives d'oxopiperazine pour le traitement de la douleur et de l'epilepsie
WO2011056985A2 (fr) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Composés hétérocycliques substitués
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
KR20130095772A (ko) 2010-10-05 2013-08-28 퍼듀 퍼머 엘피 나트륨 채널 차단제로서 퀴나졸린 화합물
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
AU2012328561A1 (en) 2011-10-28 2014-04-17 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
WO2013086229A1 (fr) * 2011-12-07 2013-06-13 Amgen Inc. Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques
WO2013122897A1 (fr) * 2012-02-13 2013-08-22 Amgen Inc. Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤としてのスルホンアミド

Also Published As

Publication number Publication date
CA2944115A1 (fr) 2015-10-08
WO2015151001A1 (fr) 2015-10-08
TW201623264A (zh) 2016-07-01
EP3126360A1 (fr) 2017-02-08
AU2015242219A1 (en) 2016-10-06
US20170137415A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
MX2016017147A (es) Compuestos de indazole substituidos como inhibidores de irak4.
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
GEP20207102B (en) Sulfonamides as modulators of sodium channels
EP3010506A4 (fr) Utilisation de pridopidine à forte dose pour traiter la maladie de huntington
MX2015010125A (es) Derivados de piridazinona-amidas.
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
MX371050B (es) Compuestos para tratar atrofia muscular espinal.
GEP20186903B (en) Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
BR112017010440A2 (pt) administração sublingual de riluzol
BR112017010423A2 (pt) formulação sublingual de riluzol
PH12017500747A1 (en) Heterocyclic compound
MX372772B (es) Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes.
PH12017500737A1 (en) Kcnq2-5 channel activator
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
GT201400242A (es) "nuevos compuestos de pirazol"
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
IN2014MN01469A (fr)